The release of the long-awaited outcomes trial for Sanofi/Regeneron Pharmaceuticals Inc.'s PCSK9 inhibitor at the American College of Cardiology Scientific Sessions was a big news event for the cholesterol-lowering field, but the announcement that the firms will lower the price of Praluent (alirocumab) in the US in line with a recommendation from the Institute for Clinical and Economic Review (ICER) stands out for the potential to set a precedent for the pharmaceutical industry.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?